These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19483700)

  • 21. Generic Truvada approved.
    AIDS Patient Care STDS; 2009 May; 23(5):395. PubMed ID: 19422066
    [No Abstract]   [Full Text] [Related]  

  • 22. [One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful].
    Warpakowski A
    MMW Fortschr Med; 2009 Apr; 151(18):54-5. PubMed ID: 19769077
    [No Abstract]   [Full Text] [Related]  

  • 23. Study shows people can safely switch to Atripla.
    Proj Inf Perspect; 2008 Dec; (47):2. PubMed ID: 19226673
    [No Abstract]   [Full Text] [Related]  

  • 24. Tenofovir/emtricitabine combination results in lower bone-mineral density.
    AIDS Patient Care STDS; 2010 Apr; 24(4):265-6. PubMed ID: 20405529
    [No Abstract]   [Full Text] [Related]  

  • 25. A once-daily combination tablet (Atripla) for HIV.
    Med Lett Drugs Ther; 2006 Sep; 48(1244):78-9. PubMed ID: 17001298
    [No Abstract]   [Full Text] [Related]  

  • 26. [Once daily administration improves therapy adherence in HAART. New substance class with more powerful reserves against virus resistance].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():86-9. PubMed ID: 11373792
    [No Abstract]   [Full Text] [Related]  

  • 27. Case study: an active, 24-year-old woman positive for HIV.
    JAAPA; 2006 Jan; Suppl():14. PubMed ID: 16429964
    [No Abstract]   [Full Text] [Related]  

  • 28. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infectious diseases. Doubts dispelled about HIV prevention.
    Cohen J
    Science; 2015 Mar; 347(6226):1055-6. PubMed ID: 25745140
    [No Abstract]   [Full Text] [Related]  

  • 30. [Complete HAART in a single pill. New milestone for improving compliance].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():40-1. PubMed ID: 19024916
    [No Abstract]   [Full Text] [Related]  

  • 31. Once-daily dosing and the treatment of HIV disease.
    Laurence J
    AIDS Read; 2006 Sep; 16(9):444-5. PubMed ID: 17024761
    [No Abstract]   [Full Text] [Related]  

  • 32. [One pill--all HAART. Complete divergent HAART in a single tablet per day].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():76-7. PubMed ID: 19024926
    [No Abstract]   [Full Text] [Related]  

  • 33. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug interactions. Super pills-the treatments of the future?
    TreatmentUpdate; 2006; 18(3):2-3. PubMed ID: 17209236
    [No Abstract]   [Full Text] [Related]  

  • 35. Triple combinations regimens for HIV.
    Lancet Infect Dis; 2003 Nov; 3(11):682. PubMed ID: 14603888
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical decisions. Preexposure prophylaxis for HIV prevention.
    Abdool Karim SS; Gray GE; Martinson N
    N Engl J Med; 2012 Aug; 367(5):462-5. PubMed ID: 22784042
    [No Abstract]   [Full Text] [Related]  

  • 37. High rate of virologic failure with once-daily ddI/3TC/TDF.
    IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
    [No Abstract]   [Full Text] [Related]  

  • 38. [Medication change due to side effects or possible long-term complications. Side effect management with vision].
    Sankawa Y
    MMW Fortschr Med; 2009 Apr; 151(18):35. PubMed ID: 19769072
    [No Abstract]   [Full Text] [Related]  

  • 39. Tenofovir drug interactions: ddI and d4T.
    TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
    [No Abstract]   [Full Text] [Related]  

  • 40. Gilead is going strong.
    Levenson E
    Fortune; 2009 Mar; 159(6):51-2. PubMed ID: 19351097
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.